Because of concerns for anthracycline-induced cardiac toxicity, many physicians are willing to avoid anthracycline-containing regimens in patients who achieve a pCR or, even in patients who do not have a pCR, when the residual tumor is small (especially pN0 cases), as observed for patients in the ER-negative cohort in the present study. This evidence concerns the gene ESR1 and neoplasm.